Status:
COMPLETED
Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to compare the liquid suspension form of AZD 2624 to a tablet form of the same drug. This study will also study the effect of food on the tablet form of the drug.
Eligibility Criteria
Inclusion
- Healthy male and female volunteers
Exclusion
- Donation of plasma or blood products within one month of of screening
- Clinically relevant abnormalities in physical examination, vital signs,ECG, clinical chemistry, hematology, or urinalysis.
- Previous participation in an AD2624 study.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2009
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT00867685
Start Date
March 1 2009
End Date
April 1 2009
Last Update
April 30 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Philadelphia, Pennsylvania, United States